Mounjaro vs. Ozempic vs. Wegovy: Full 2026 Comparison

Mounjaro, Ozempic, and Wegovy are three names you have probably seen more than a few times in 2026. They show up in news articles, social media feeds, and conversations at the doctor's office. But despite the shared spotlight, these medications are not the same thing. They have different active ingredients, different approved uses, and different clinical track records.

If you are trying to figure out which one applies to you, or simply want to understand what the difference actually is, this guide breaks it down clearly.

*This article is for educational purposes only and does not constitute medical advice. Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. Individual results vary. Consult a licensed healthcare provider before starting any medication.*

---

Quick Reference: Mounjaro vs. Ozempic vs. Wegovy

One important note before we go further: these three drugs are all injectable GLP-1 receptor agonists, but Mounjaro does something that Ozempic and Wegovy do not. It also activates a second hormone receptor, which appears to account for some of the differences in weight loss data. We will get into that below.

---

Understanding the Medications

Ozempic (Semaglutide for Diabetes)

Ozempic contains semaglutide and is FDA-approved for adults with type 2 diabetes to improve blood sugar control and reduce the risk of major cardiovascular events. It is injected once weekly.

Its doses top out at 2 mg per week. While Ozempic is frequently prescribed off-label for weight management, it was not designed or approved for that purpose. The weight-loss version of semaglutide, at a higher dose, is Wegovy.

Wegovy (Semaglutide for Weight Management)

Wegovy and Ozempic are both semaglutide products from Novo Nordisk, with Wegovy dosed up to 2.4 mg per week — higher than Ozempic's 2 mg ceiling. Wegovy is FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related health condition, such as high blood pressure or elevated cholesterol.

Because Wegovy was developed and studied specifically for weight loss, its clinical data in that context is more robust than Ozempic's. It goes through a dose titration schedule that takes about 16 to 20 weeks to reach the full 2.4 mg dose, which helps reduce side effects during the adjustment period.

Mounjaro (Tirzepatide for Diabetes)

Mounjaro contains tirzepatide, a newer molecule that differs from semaglutide in a meaningful way. While semaglutide activates only GLP-1 receptors, tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously.

GIP is another incretin hormone involved in insulin secretion and fat metabolism. The dual activation appears to produce more pronounced metabolic effects in many patients, which is reflected in the clinical weight loss data.

Mounjaro is FDA-approved for type 2 diabetes. Its weight-loss counterpart, Zepbound (also tirzepatide), is FDA-approved specifically for weight management. Mounjaro is commonly prescribed off-label for weight loss, particularly where Zepbound availability is limited.

---

How They Work: The Science

All three medications belong to the GLP-1 receptor agonist class. GLP-1 is a hormone released naturally after you eat. It tells your brain you are full, slows the rate at which food leaves your stomach, and signals the pancreas to release insulin.

By mimicking this hormone at a sustained level, these medications reduce appetite and lower overall caloric intake. This is the core mechanism behind the weight loss associated with all three drugs.

Mounjaro's advantage is the GIP receptor activation it adds on top of this. GIP is thought to influence fat storage, and early evidence suggests the GIP pathway may enhance the effects of GLP-1 activation. The result in clinical trials has been greater average weight loss for tirzepatide compared to semaglutide, though individual responses vary considerably.

---

Weight Loss Results: What the Research Shows

This is where the differences become most visible.

Ozempic: Because Ozempic was studied for diabetes, not weight loss, its weight loss data comes primarily from diabetes trials. In those studies, patients on semaglutide 1 mg and 2 mg typically lost around 4 to 6 percent of body weight over 30 to 40 weeks. Weight loss was a secondary outcome, not the primary goal.

Wegovy: The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with overweight or obesity over 68 weeks. Participants on semaglutide 2.4 mg lost an average of 14.9 percent of body weight compared to 2.4 percent with placebo. [1] That is a meaningful difference, and it established semaglutide as an effective weight management tool when used at the Wegovy dose.

Mounjaro/Tirzepatide: The SURMOUNT-1 trial, also published in the New England Journal of Medicine, followed adults with obesity over 72 weeks. Those on tirzepatide 15 mg lost an average of 22.5 percent of body weight, compared to 2.4 percent with placebo. [2] The 10 mg dose produced an average loss of 21.4 percent, and the 5 mg dose produced 16.0 percent.

A direct comparison trial called SURPASS-2 put tirzepatide head-to-head against semaglutide 1 mg (the Ozempic dose) in patients with type 2 diabetes. Tirzepatide 15 mg produced an average weight reduction of 13.1 percent compared to 8.3 percent for semaglutide 1 mg. [3]

The most clinically relevant head-to-head study for people focused specifically on weight management is SURMOUNT-5, published in 2025. This trial compared tirzepatide directly against semaglutide 2.4 mg, the Wegovy dose, in adults with obesity who did not have type 2 diabetes. At 72 weeks, participants on tirzepatide lost an average of 20.2 percent of their body weight compared to 13.7 percent for those on semaglutide 2.4 mg. That is roughly 47 percent greater relative weight loss in favor of tirzepatide. [4]

These results apply to the specific branded medications and doses used in those trials. Compounded versions of semaglutide and tirzepatide are not FDA-approved and are not equivalent to branded products. Individual results with any GLP-1 medication depend on adherence, diet, activity level, starting weight, and individual metabolic factors.

---

Side Effects: What to Expect

The side effect profiles of all three medications are similar because they share the same fundamental mechanism. The most common issues are gastrointestinal.

Common side effects across all three:

• Nausea (most common, especially at dose increases)
• Vomiting
• Diarrhea
• Constipation
• Reduced appetite
• Stomach discomfort

These effects are most pronounced during dose titration, the first few months when your dose is being gradually increased. Most people find that side effects ease significantly once they reach and stabilize at their maintenance dose.

Serious but less common risks:

• Pancreatitis (inflammation of the pancreas)
• Gallbladder disease, including gallstones
• Kidney injury (often related to dehydration from nausea and vomiting)
• Changes in heart rate

Contraindications shared by all three:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planning to become pregnant
• Known hypersensitivity to the active ingredient

There is not strong clinical evidence that any of these three drugs causes meaningfully more or fewer side effects than the others, though individual tolerance varies. Some patients who experience intolerable nausea on semaglutide tolerate tirzepatide better, and vice versa. Working with a provider who can adjust your dose progression is the most effective way to manage side effects.

---

Cost: Brand vs. Compounded Options

Brand-name pricing for all three medications is substantial without insurance coverage:

• Ozempic: approximately $900 to $1,000 per month without insurance
• Wegovy: approximately $1,300 to $1,400 per month without insurance
• Mounjaro: approximately $1,000 to $1,100 per month without insurance

Insurance coverage varies considerably. Many commercial plans cover Ozempic or Mounjaro for type 2 diabetes, but coverage for Wegovy (weight management) is less consistent. Medicare currently does not cover GLP-1 medications for weight loss alone.

Compounded alternatives are available at significantly lower cost. Compounded semaglutide and compounded tirzepatide are prepared by licensed compounding pharmacies under patient-specific prescriptions. These are not FDA-approved medications and are not the same as branded products, but they use the same active pharmaceutical ingredients at a fraction of the cost.

Compounded semaglutide programs typically run $150 to $300 per month. Compounded tirzepatide programs typically run $250 to $400 per month. These prices usually include the medical consultation and medication, though they vary by provider.

---

Availability and Access

Brand-name medications have experienced significant shortages over the past two years as demand has surged. Ozempic and Wegovy availability has improved in 2026, though pharmacy stock still varies by region. Mounjaro shortages have also been an issue.

Compounded alternatives remain more consistently available through telehealth platforms. Compounding pharmacies produce medication on a per-prescription basis rather than at fixed manufacturing scale, which makes availability more predictable for patients.

Access to all of these medications, brand or compounded, requires a prescription from a licensed healthcare provider. Telehealth platforms have made that access significantly easier by removing the need for in-person appointments in most cases.

---

Which One Is Right for You?

The right medication depends on several factors that your provider is best positioned to evaluate. Here is a general framework:

Consider semaglutide (Ozempic or Wegovy) if:

• You have type 2 diabetes and your provider recommends Ozempic
• You are focused on weight management and want to use the specifically approved version (Wegovy)
• Semaglutide is covered by your insurance for your specific indication
• Cost or access makes compounded semaglutide the most practical option

Consider tirzepatide (Mounjaro) if:

• You have type 2 diabetes and your provider prefers tirzepatide's dual mechanism
• You have tried semaglutide without sufficient response
• Clinical data showing higher average weight loss is relevant to your goals
• Your provider recommends tirzepatide based on your health profile

Neither semaglutide nor tirzepatide is universally better. For most people who have never tried a GLP-1 medication before, either is a reasonable starting point under provider supervision. For those who have tried semaglutide and want to evaluate a different approach, tirzepatide is a logical next step to discuss with your provider.

---

Frequently Asked Questions

Is Mounjaro stronger than Ozempic and Wegovy?

Clinical trials show tirzepatide (Mounjaro) produces higher average weight loss than semaglutide at the doses studied. The SURMOUNT-1 trial showed up to 22.5 percent body weight reduction with tirzepatide 15 mg, compared to about 14.9 percent with semaglutide 2.4 mg in the STEP 1 trial. [1][2] The 2025 SURMOUNT-5 head-to-head trial, which directly compared tirzepatide against semaglutide 2.4 mg in adults with obesity, showed tirzepatide produced approximately 47 percent greater relative weight loss (20.2 percent vs. 13.7 percent). [4] That said, "stronger" is not the same as "better for you specifically." Individual response varies, and the right choice depends on your health profile, not just the headline number.

Can I get these medications without insurance?

Yes. Telehealth platforms offer compounded semaglutide and compounded tirzepatide at significantly lower cost than brand-name medications. Compounded versions are prepared by licensed compounding pharmacies under a clinician prescription; they are not FDA-approved, not evaluated by the FDA for safety or efficacy, and are not interchangeable with branded products.

Why does Wegovy cause more weight loss than Ozempic if they have the same ingredient?

The dose is the primary reason. Wegovy reaches a maximum dose of 2.4 mg per week of semaglutide. Ozempic tops out at 2 mg per week. Higher doses generally produce greater appetite suppression and weight reduction, which is why Wegovy was specifically developed and studied at a higher dose for weight management.

How long does it take to see results?

Most people begin noticing appetite changes within the first two to four weeks. Visible weight changes typically appear within the first four to eight weeks. Meaningful weight loss, the kind reflected in clinical trial data, accumulates over several months as doses are gradually increased. Plateaus are common and can be addressed by your provider through dose adjustments or behavioral support.

Are there oral versions of these medications?

Rybelsus is an oral tablet form of semaglutide approved for type 2 diabetes. Compounded oral semaglutide is available through some telehealth platforms. There is no oral brand-name version of tirzepatide approved for weight management as of 2026, though compounded oral tirzepatide is available in some programs. Oral bioavailability and clinical data differ from injectable forms. Ask your provider which option fits your situation.

Can I switch from one to another?

In many cases, yes. If you are not achieving your goals on semaglutide, your provider may recommend transitioning to tirzepatide, and vice versa. Switching requires a new evaluation and typically involves restarting at a lower dose. Never switch medications without discussing it with your provider first.

---

*Ready to explore your options? Find out if you qualify at Prescriva today.*

---

Disclaimers

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.

Compounding Disclaimer: Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products (Ozempic, Wegovy, or Rybelsus). Compounded tirzepatide is not the same as, equivalent to, or interchangeable with FDA-approved tirzepatide products (Mounjaro or Zepbound).

Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.

Brand Disclaimer: Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Prescriva is not affiliated with, endorsed by, or sponsored by these companies. Prices subject to change.

---

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021;384(11):989-1002. PMID: 33567185. doi:10.1056/NEJMoa2032183

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med.* 2022;387(3):205-216. PMID: 35658024. doi:10.1056/NEJMoa2206038

1. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. *N Engl J Med.* 2021;385(6):503-515. PMID: 34170647. doi:10.1056/NEJMoa2107519

1. Aronne LJ, Sattar N, Horn DB, et al. Tirzepatide versus Semaglutide for the Treatment of Obesity. *N Engl J Med.* 2025;392(4):321-332. PMID: 39754679. doi:10.1056/NEJMoa2407001